Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 5/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 4/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 3/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonazepam SCHEMBL38899 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL5501860 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13747803 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13746712 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29369721 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29743048 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL28390843 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL31321724 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL9834407 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL20771795 | 0.98 | GABRA1 (0.96) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207280-A1 | LAMOTRIGINE HYDRATE CRYSTAL FORM, PREPARATION METHOD THEREFOR, AND COMPOSITION CONTAINING SAME | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2024-06-27 | — | — | US | claimed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| WO-2022218437-A1 | LAMOTRIGINE HYDRATE CRYSTAL FORM, PREPARATION METHOD THEREFOR, AND COMPOSITION CONTAINING SAME | 上海奥科达生物医药科技有限公司 | 2022-10-20 | — | — | WO | claimed |
| EP-4731288-A1 | AEROSOL DELIVERY SYSTEMS | Miist Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595237-B2 | Lamotrigine hydrate crystal form, preparation method therefor, and composition containing same | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260080167-A1 | SYSTEM AND METHOD FOR VALIDATING LANGUAGE MODEL OUTPUT WITH NATURAL LANGUAGE PROCESSING | SAS INSTITUTE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| EP-4687835-A1 | A BIPHASIC LIQUID PHARMACEUTICAL COMPOSITION OF AN ANTICONVULSANT DRUG AND THE PROCESS OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027057-A1 | THERAPEUTIC FORMULATIONS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2026-01-29 | — | — | US | disclosed |
| CN-111132549-B | Long-acting control agent for ectoparasites of animals | 三井化学AGRO株式会社 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3966159-A1 | SUBSTRATES FOR SURFACE-ENHANCED RAMAN SPECTROSCOPY AND METHODS FOR MANUFACTURING SAME | The Research Foundation for The State University of New York (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| WO-2022017945-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017909-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017962-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | GABRA1 29/4885GABRA5 68/4885GABRA3 49/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | GABRA1 667/4885GABRA5 846/4885GABRA3 535/4885 |
| US-20260080167-A1 | SYSTEM AND METHOD FOR VALIDATING LANGUAGE MODEL OUTPUT WITH NATURAL LANGUAGE PROCESSING | SET, LIN28A, HNRNPLL | GABRA1 2756/4885GABRA5 2355/4885GABRA3 2818/4885 |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | GABRA1 3000/4885GABRA5 3226/4885GABRA3 3578/4885 |
| US-20260027057-A1 | THERAPEUTIC FORMULATIONS AND USES THEREOF | CHRNA10, CHRNA7, CHRNA6 | GABRA1 43/4885GABRA5 49/4885GABRA3 41/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | GABRA1 4467/4885GABRA5 4402/4885GABRA3 4690/4885 |
| US-12595237-B2 | Lamotrigine hydrate crystal form, preparation method therefor, and composition containing same | CACNA1S, CACNA1D, CACNA1F | GABRA1 479/4885GABRA5 621/4885GABRA3 1164/4885 |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | HDAC5, NR5A2, HRH4 | GABRA1 773/4885GABRA5 252/4885GABRA3 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.